Research Coverage of Japanese Listed Companies, Shared Research Inc

Shared Research

Research Coverage of Japanese Listed Companies

Shared Research Inc

Pioneering research coverage of Japanese listed companies. Now customizable and interactive for global institutional investors. Corporate access reimagined.

Equity Bottom-Up

<ul><li>The company reported YoY increases in sales (3.7%), operating profit (26.3%), recurring profit (11.6%), and net income (0.7%).</li><li>Pharmaceuticals Business sales fell 1.6% YoY to JPY7.1bn, with notable declines in Domestic and Overseas Pharmaceuticals segments.</li><li>R&D expenses were JPY1.6bn (20.4% of sales, excluding royalty income); significant pipeline developments include SI-6603 and SI-449.</li></ul>

The company reported YoY increases in sales (3.7%), operating profit (26.3%), recurring profit (11.6%), and net income (0.7%).Pharmaceuticals Business sales fell 1.6% YoY to JPY7.1bn, with notable declines in Domestic and Overseas Pharmaceuticals segments.R&D expenses were JPY1.6bn (20.4% of sales, excluding royalty income); significant pipeline developments include SI-6603 and SI-449.

Seikagaku Corp (4548 JP): Q1 FY03/25 flash update

Japan

SEIKAGAKU CORPORATION mainly manufactures complex-carbohydrate-base medicines and raw materials used for the pharmaceutical products.  The Company also manufactures and sells clinical reagents, diagnosis reagents, external medicine, medical equipment, and health food.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Seikagaku Corp (4548 JP): Q1 FY03/25 flash update

The company reported YoY increases in sales (3.7%), operating profit (26.3%), recurring profit (11.6%), and net income (0.7%). Pharmaceuticals...

Shared Research